Case Overview (Settlement announced 2006, United States)
GlaxoSmithKline Holdings (Americas) Inc. & Subsidiaries v. Commissioner is best known not for a litigated opinion, but for the IRS’s September 11, 2006 announcement that it accepted GSK’s settlement offer in what the IRS called its largest tax dispute. The IRS stated GSK would pay approximately $3.4 billion (including interest) and abandon a $1.8 billion refund claim, resolving transfer pricing issues for tax years 1989 through 2005. (IR-2006-142)
Key Facts (verified from public sources)
- The settlement was announced on September 11, 2006 while the matter was pending in the U.S. Tax Court. (IR-2006-142)
- The Tax Court controversy involved adjustments for tax years 1989–2000; the IRS and GSK also reached agreement for 2001–2005. (IR-2006-142)
- The dispute involved intercompany transactions for certain GSK “heritage” pharmaceutical products, focusing on the level of U.S. profits after intercompany payments reflecting (among other things) product intangibles developed by and trademarks owned by GSK’s U.K. parent, versus the value of marketing and other U.S. contributions. (IR-2006-142)
- Under the settlement, the IRS stated GSK conceded over 60% of the total amount the parties had put in issue for the 1989–2000 Tax Court years. (IR-2006-142)
- Practitioner commentary reported the IRS had proposed approximately $4.5 billion in tax deficiencies for 1989–2000, and that the case was scheduled for trial in February 2007 before settlement. (Miller & Chevalier)
The Dispute (what the IRS said was at issue)
The IRS described the Tax Court case as a classic Section 482 / arm’s-length allocation problem in a pharmaceutical group:
- GSK’s U.S. entities made intercompany payments to foreign affiliates that took into account non-U.S. product intangibles and U.K.-owned trademarks, as well as other non-U.S. activities.
- The IRS questioned whether those payments left too little U.S. profit, given the value of GSK’s U.S. marketing and other contributions for the “heritage” products. (IR-2006-142)
Contemporaneous practitioner discussion framed the parties’ positions more explicitly:
- GSK’s position (as reported): the U.S. affiliate was essentially a routine distributor, performing routine marketing/selling functions; to the extent intangibles drove profits, they were primarily owned and/or developed outside the U.S.
- IRS position (as reported): the U.S. affiliate was not merely a distributor; it was a licensee and the owner for tax purposes of valuable product and marketing intangibles associated with the licensed products. (Miller & Chevalier)
Important limitation: the IRS announcement and other public summaries do not disclose the specific transfer pricing methods or comparables used by either side. Accordingly, this matter is best treated as an instructive settlement fact pattern (intangibles + U.S. marketing contributions) rather than a precedent on method selection.
Procedural point: the APA discrimination claim
In addition to the transfer pricing adjustments, public practitioner commentary reported that the parties also settled GSK’s “APA discrimination” claim—i.e., an allegation that GSK was treated differently in the APA program than similarly situated U.S.-based pharmaceutical companies. (Miller & Chevalier)
Outcome / “Holding”
There is no published merits decision, because the dispute was resolved by settlement.
Per the IRS announcement (IR-2006-142):
- GSK would pay approximately $3.4 billion (including interest).
- GSK would abandon a $1.8 billion refund claim.
- The settlement resolved the parties’ transfer pricing dispute for 1989–2005, including the 1989–2000 years pending in Tax Court and agreed outcomes for 2001–2005.
- For the Tax Court years, GSK conceded over 60% of the total amount put in issue by the parties.
Takeaways for Practitioners
- Marketing contributions can drive residual profit debates in pharma and other branded-product industries—document functions, control, and decision-making that support (or refute) “marketing intangible” claims.
- Be explicit about what intercompany payments cover (product intangibles, trademarks, services, etc.) and whether U.S. activities are being compensated only as “routine” or as value-creating.
- Settlement posture matters in multi-year cases: long audit cycles, interest, and refund claims can materially affect leverage and economics.
- Don’t over-read settlements as method precedent: the public record here supports the issues in dispute, but not a method-by-method roadmap.
Related Content
For practical guidance on supporting intangible-related pricing, see Documentation for Intangibles. For core concepts that framed the dispute, review the Arm's Length Principle and (as a general tool in U.S. practice) the Comparable Profits Method.
Frequently Asked Questions
Q1: Was there an official court decision on the merits?
No. The dispute settled while pending in the U.S. Tax Court, so there is no precedential merits opinion. The key primary source is the IRS settlement announcement IR-2006-142.
Q2: What years did the settlement cover?
The IRS announced the settlement resolved transfer pricing issues for 1989 through 2005. The Tax Court dispute concerned 1989–2000, and the parties also reached agreement for 2001–2005. (IR-2006-142)
Q3: What was paid, and what else did GSK give up?
The IRS stated GSK would pay approximately $3.4 billion (including interest) and abandon a $1.8 billion refund claim. (IR-2006-142)
Q4: What transfer pricing issue drove the case?
The IRS described a dispute over the level of U.S. profits reported after intercompany payments reflecting non-U.S. product intangibles and U.K.-owned trademarks, versus the value of U.S. marketing and other contributions for certain “heritage” products. (IR-2006-142)
Q5: Why does this settlement still matter for TP practice?
It shows the potential scale of intangibles-driven exposure and the recurring controversy over whether a U.S. affiliate is a routine distributor or should share more in residual profits because of U.S. market-development and marketing contributions—even when no litigated opinion results.
